Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 31

Related Articles by Review for PubMed (Select 18398735)

1.

Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.

Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, Issa JP, Kantarjian H.

Leuk Lymphoma. 2008 Apr;49(4):690-5. doi: 10.1080/10428190701882146.

2.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Epub 2013 Oct 15. Review.

PMID:
24309530
3.

The role of decitabine in the treatment of myelodysplastic syndromes.

Atallah E, Kantarjian H, Garcia-Manero G.

Expert Opin Pharmacother. 2007 Jan;8(1):65-73. Review.

PMID:
17163808
4.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
5.

[Hypomethylating agents for the treatment of myelodysplastic syndromes].

Itzykson R, Fenaux P.

Bull Cancer. 2011 Aug;98(8):927-34. doi: 10.1684/bdc.2011.1411. Review. French.

PMID:
21821482
6.

Decitabine in the treatment of myelodysplastic syndromes.

Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F.

Expert Rev Anticancer Ther. 2010 Jan;10(1):9-22. doi: 10.1586/era.09.164. Review.

PMID:
20014881
7.

Therapy with azanucleosides for myelodysplastic syndromes.

Quintás-Cardama A, Santos FP, Garcia-Manero G.

Nat Rev Clin Oncol. 2010 Aug;7(8):433-44. doi: 10.1038/nrclinonc.2010.87. Epub 2010 Jun 15. Review.

PMID:
20551943
8.

Decitabine in myelodysplastic syndromes.

Saba HI, Wijermans PW.

Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. Review.

PMID:
16015501
9.

Practical recommendations for hypomethylating agent therapy of patients with myelodysplastic syndromes.

Steensma DP, Stone RM.

Hematol Oncol Clin North Am. 2010 Apr;24(2):389-406. doi: 10.1016/j.hoc.2010.02.012. Review.

PMID:
20359633
10.

Demethylating agents in myeloid malignancies.

Garcia-Manero G.

Curr Opin Oncol. 2008 Nov;20(6):705-10. doi: 10.1097/CCO.0b013e328313699c. Review.

11.

[Demethylating medication in myelodysplastic syndrome].

Manson ML, Derissen EJ, Wijermans PW, Schellens JH, Beijnen JH.

Ned Tijdschr Geneeskd. 2012;156(4):A3167. Review. Dutch.

PMID:
22278034
12.

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.

Estey EH.

Leukemia. 2013 Sep;27(9):1803-12. doi: 10.1038/leu.2013.173. Epub 2013 Jun 12. Review.

PMID:
23757301
13.

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.

Silverman LR, Mufti GJ.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S12-23. Review.

PMID:
16341236
14.

In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.

Hackanson B, Robbel C, Wijermans P, Lübbert M.

Ann Hematol. 2005 Dec;84 Suppl 1:32-8. Review.

PMID:
16292549
15.

Recent experience with decitabine in MDS.

Kantarjian HM.

Clin Adv Hematol Oncol. 2007 Feb;5(2):140. Review. No abstract available.

PMID:
17344803
16.

Pharmacokinetic evaluation of decitabine for the treatment of leukemia.

Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E.

Expert Opin Drug Metab Toxicol. 2011 May;7(5):661-72. doi: 10.1517/17425255.2011.575062. Review.

PMID:
21500965
17.

Safety and efficacy of azacitidine in myelodysplastic syndromes.

Vigil CE, Martin-Santos T, Garcia-Manero G.

Drug Des Devel Ther. 2010 Sep 24;4:221-9. Review.

18.

Inhibitors of DNA methylation in the treatment of hematological malignancies and MDS.

Leone G, Voso MT, Teofili L, Lübbert M.

Clin Immunol. 2003 Oct;109(1):89-102. Review.

PMID:
14585280
19.

Decitabine and its role in the treatment of hematopoietic malignancies.

Plimack ER, Kantarjian HM, Issa JP.

Leuk Lymphoma. 2007 Aug;48(8):1472-81. Review.

PMID:
17701577
20.

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.

Santini V, Prebet T, Fenaux P, Gattermann N, Nilsson L, Pfeilstöcker M, Vyas P, List AF.

Leuk Res. 2014 Dec;38(12):1381-91. doi: 10.1016/j.leukres.2014.09.008. Epub 2014 Sep 22. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk